Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database by Ju-Young Kim et al.
Kim et al. BMC Cardiovascular Disorders 2012, 12:60
http://www.biomedcentral.com/1471-2261/12/60RESEARCH ARTICLE Open AccessUtilization of evidence-based treatment in elderly
patients with chronic heart failure: using Korean
Health Insurance claims database
Ju-Young Kim1†, Hwa-Jung Kim2†, Sun-Young Jung3, Kwang-Il Kim4, Hong Ji Song5, Joong-Yub Lee6,
Jong-Mi Seong7 and Byung-Joo Park7*Abstract
Background: Chronic heart failure accounts for a great deal of the morbidity and mortality in the aging population.
Evidence-based treatments include angiotensin-2 receptor blockers (ARBs), angiotensin-converting enzyme
inhibitors (ACE-I), beta-blockers, and aldosterone antagonists. Underutilization of these treatments in heart failure
patients were frequently reported, which could lead to increase morbidity and mortality. The aim of this study was
to evaluate the utilization of evidence-based treatments and their related factors for elderly patients with chronic
heart failure.
Methods: This is retrospective observational study using the Korean National Health Insurance claims database. We
identified prescription of evidence based treatment to elderly patients who had been hospitalized for chronic heart
failure between January 1, 2005, and June 30, 2006.
Results: Among the 28,922 elderly patients with chronic heart failure, beta-blockers were prescribed to 31.5%, and
ACE-I or ARBs were prescribed to 54.7% of the total population. Multivariable logistic regression analyses revealed
that the prescription from outpatient clinic (prevalent ratio, 4.02, 95% CI 3.31–4.72), specialty of the healthcare
providers (prevalent ratio, 1.26, 95% CI, 1.12–1.54), residence in urban (prevalent ratio, 1.37, 95% CI, 1.23–1.52) and
admission to tertiary hospital (prevalent ratio, 2.07, 95% CI, 1.85–2.31) were important factors associated with
treatment underutilization. Patients not given evidence-based treatment were more likely to experience dementia,
reside in rural areas, and have less-specialized healthcare providers and were less likely to have coexisting
cardiovascular diseases or concomitant medications than patients in the evidence-based treatment group.
Conclusions: Healthcare system factors, such as hospital type, healthcare provider factors, such as specialty, and
patient factors, such as comorbid cardiovascular disease, systemic disease with concomitant medications, together
influence the underutilization of evidence-based pharmacologic treatment for patients with heart failure.
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Chronic heart failure (CHF) is a significant health bur-
den worldwide and affects approximately 10% of indivi-
duals over 65 years of age [1]. The annual incidence of
new heart failure events per 1,000 individuals is 15.2 for
those aged 65 to 74, 31.7 for those aged 75 to 84, and
65.2 for those over 85 years of age [1]. Korea has an
aging population, and the increased incidence of age-
related chronic diseases, including hypertension, dia-
betes, angina or other forms of cardiovascular disease,
has negatively impacted the health and lives of elderly
individuals.
Heart failure accounts for a great deal of the morbidity
and mortality in the population, and the estimated 5-
year age-adjusted mortality rate after a diagnosis of heart
failure is 59% for men and 45% for women [2].
Evidence-based treatments that have been shown to
decrease mortality rates [3,4] include angiotensin-2 re-
ceptor blockers (ARBs), angiotensin-converting enzyme
inhibitors (ACE-I), beta-blockers, and aldosterone
antagonists. However, several studies have shown that
these treatments are underutilized and are often pre-
scribed at lower dose levels [5-10]. Factors related to the
underutilization of evidence-based treatments include a
lack of initiation or early discontinuation. The causes of
this lack of initiation include the contraindication of
drug use, lack of knowledge, lack of expertise for using
these drugs, lack of time, and economic restraints [9].
However, in many cases, the reasons for underutilizing
evidence-based therapy are unclear. Some evidence has
been collected from several randomized clinical trials
(RCTs), but most RCTs have limited generalizability for
treatment options because these trials typically have
strict inclusion and exclusion criteria. Euro Heart sur-
veys found that among 10,701 heart failure patients,
only 1,346 were eligible to participate in the majority
of RCTs [11]. However, these findings do not explain
the underutilization of evidence-based treatment in eli-
gible individuals, and elderly CHF patients could sig-
nificantly benefit from evidence-based treatment
[12,13].
The causes of treatment underutilization may include
the fear of polypharmacy, inaccurate perceptions con-
cerning adverse effects, and contraindications. However,
the mortality rate of patients with renal insufficiency was
lower for those who received ACE-I, beta-blockers, sta-
tins, and aspirin [14]. Beta-blockers can be prescribed
safely to patients with diabetes [15-17] and chronic ob-
structive pulmonary disease [18-21], and this treatment
significantly decreases the morbidity and mortality
caused by heart failure. Also, the utilization of evidence-
based treatment for patients with heart failure can sig-
nificantly reduce heart failure-related hospital admission
and mortality [12,22,23].We evaluated the utilization of evidence-based treat-
ments in elderly patients with heart failure using a claims
database so as to assure generalizability for
elderly individuals. We also studied the patient and
provider factors that were related to the utilization of
each drug.Methods
Data source
Patients were identified from the Korean Health Insur-
ance Review and Assessment Service database (KHIRA),
which contains medical claims data for the entire Korean
population [24] as a result of the National Insurance
Health System. Patients pay an average of 30% of the
total medical costs related to almost all diseases. Health-
care providers submit reports concerning the medical
services performed to the KHIRA for a review of the
medical costs incurred. These reports contain informa-
tion on the diagnosis that has been coded in accordance
with the International Classification of Diseases Tenth
Revision [ICD-10] as well as information related to out-
patient or inpatient status, drug name, dosage, prescrip-
tion date, duration, and method of administration. The
KHIRA provided data with the individual identifier
removed, in accordance with the Act on the Protection
of Personal Information Maintained by Public Agencies.
Thus, the database included an unidentifiable code
representing each individual with data concerning the
patients’ age, gender, diagnosis and lists of prescribed
drugs.
The database contained information regarding
1,093,262 elderly patients aged above 65 years and
11,842,586 prescriptions from January 1, 2005, to June
30, 2006.
This study was approved by the institutional review
board of the Seoul National University Bundang Hospital
with reference number of B-1011-115-105.Study population
We identified older adults who were over the age of
65 and had been hospitalized with a primary discharge
diagnosis of heart failure (ICD-10 codes: I11, I13, and
I50) between January 1, 2005, and June 30, 2006.
Though diagnosis of heart failure by ICD-10 codes in
the KHIRA database was not validated, we tried to in-
crease diagnostic accuracy by adjusting medications
for heart failure such as digoxin, inotropics and
diuretics.
We excluded patients if they had a length of stay less
than 24 hours or did not have medication records. In
total, 28,922 patients were admitted with a primary dis-
charge diagnosis of heart failure.
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Three classes of prescription medications were evaluated
based on evidence-based treatment: ACE-I or ARB
(group A), beta-blockers (group B), and aldosterone
antagonists (Aldo group).
The utilization of evidence-based treatments was
defined as treatments that were prescribed after
hospitalization for heart failure. We prioritized groups A
and B rather than the Aldo group because the 2005
American College of Cardiology and American Heart
Association (ACC/AHA) heart failure guidelines with
the 2009 focused update [25] recommended the addition
of an aldosterone antagonist for the treatment of patients
with moderate to severe HF and the reduced ejection
fraction who could be carefully monitored for preserved
renal function and normal plasma potassium concentra-
tions. Therefore, we classified the evidence-based treat-
ment groups as A, B, Aldo, and A + B. The A + B group
was assigned if a patient received both A and B group
treatments. If a patient received A, B, and Aldo group
treatments, then the patient was assigned to the A + B
group. If a patient received A and Aldo group treat-
ments, then the patient was assigned to group A. If a pa-
tient only received Aldo group treatment, then the
patient was assigned to the Aldo group. Group B con-
sisted of patients who were given only a beta-blocker
treatment or beta-blockers in addition to aldosterone
antagonists.
Covariates
Data concerning patient age, gender, area of residence,
type of prescription resources from inpatient or outpatient
clinic and the utilization of hospital type (primary care
clinics, secondary hospitals, which typically refer to large,
community but non-teaching hospitals, or tertiary hospi-
tals, which usually refer to a teaching or university hos-
pital) were obtained from the database. Previous
cardiovascular disease histories were collected using the
diagnosis codes for angina pectoris (I20), myocardial in-
farction (I21-22 and I25.2), transient ischemic attack or is-
chemic stroke (G45-46, H34, and I60-69), peripheral
artery disease (I70-71, I73.1, I73.8-73.9, I77.1, I79.0, I79.2,
K55.1, K55.8-55.9, and Z95.8-95.9), atrial fibrillation or
flutter (I48), and valvular heart disease (I01, I05-09, and
I34-39).
We also included any medical histories of hypertension
(I11-I13 an d I15), hyperlipidemia or dyslipidemia (E78),
end-stage renal disease (I12.0, I13.1, N03.2-03.7, N05.2,
N05.7, N18-19, N25.0, Z49.0-49.2, Z94.0, and Z99.2),
chronic lung disease (I27.8, I27.9, J40-47, J68.4, J70.1, and
J70.3), chronic liver disease (B18, K70, K71, K73-74, K76,
and Z94.4), systemic cancer (C00-C26, C30-C34, C37-C41
, C43, C45-58, C60-85, C88, and C90-97), dementia (F00-
F03, F05.1, G30, and G31.1) and depression (F32-33).Concomitant medication use was adjusted in the
model. Concomitant drugs included heart failure medi-
cations, such as diuretics, calcium channel blockers,
nitrates, digoxin, amiodarone, and hydralazine, and lipid-
lowering medications, such as statins, fibrates, and ezeti-
mibe. Anti-diabetic medications were also included, such
as sulfonylurea, metformin, alpha glucosidase inhibitors,
thiazolidinediones, and insulin.
Statistical analysis
Statistical analyses were performed using SAS software,
version 9.1 (Cary, North Carolina).
We evaluated baseline characteristics with previous
cardiovascular disease, medications and other systemic
medical histories between each group of evidence based
treatment and non use group using Student’s t test for
continuous variable and chi-square test for categorical
variables,
Multivariable logistical regression model was used to
evaluate clinical factors associated with each evidence-
based group. The model incorporated the following
demographic factors (age, gender, residence area,
utilization of hospital type, specialty of health care provi-
ders and type of prescription resources), previous cardio-
vascular diseases (angina, myocardial infarction, valvular
heart disease, atrial fibrillation or flutter, transient ische-
mic attack), systemic medical diseases (hypertension,
hyperlipidemia, chronic lung disease, end stage renal dis-
ease) and concomitant medications (heart failure medi-
cation, antidiabetic drugs) by forward selection methods.
We also performed the similar multivariable logistic re-
gression analysis in subgroup who were treated with
both digoxin and diuretics, which could indicate patients
with symptom relieving treatment for heart failure. Sub-
group analysis was shown for the purpose of increasing
diagnostic accuracy for heart failure.
Results
Study population
A total of 29,104 patients were admitted with a primary
diagnosis of congestive heart failure during the study
period, although 182 patients had no medical informa-
tion recorded. Therefore, 28,922 patients were analyzed
for this study concerning the utilization of evidence-
based treatments for congestive heart failure and flow of
study population was represented in Figure 1. The base-
line characteristics of the study population are shown in
Table 1.
The mean age at the time of admission was
77.5 ± 7.0 years; 64.4% of patients were more than
75 years of age, and 72.4% of patients were female. Most
patients were admitted to tertiary hospitals, and the
coexisting cardiovascular diseases included atrial fibrilla-
tion or flutter (19.8%), transient ischemic attack (15.9%),
Figure 1 Selection of study population. ICD-10: International Classification of Disease, Tenth Revision.
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hypertension (39.4%), diabetes (34.2%), and chronic ob-
structive lung disease (34.0%).Utilization of evidence-based treatment in elderly CHF
patients
In total, 71.4% of elderly heart failure patients received
evidence-based treatment. For each treatment group
analysis, the A + B group comprised 21.7% of the total
patient group, group A made up 33.0%, group B
9.8%, and the Aldo group represented 6.9% of the total
study population.
Females composed 70% of all study patients, and
the mean age of each group was between 76 and 79 years
of age.
For the A + B group, the specialty of 96% of the
healthcare providers was internal medicine, and 82.6% of
the A + B patients were treated at tertiary hospitals.
However, the specialty of 83% of healthcare providers for
patients who were not given evidence-based treatment
(non-use group) was internal medicine, and 47.4% of
these patients were treated at tertiary hospitals.
Patients in the A + B group had higher rates of angina,
myocardial infarction, atrial fibrillation, valvular heart
disease, and diabetes compared to those in the non-use
group. However, dementia was more pronounced in the
non-use group. Patients in the A + B group were more
likely to receive symptom-relieving heart failure drugs,
such as diuretics, digoxin, and other inotropics, than
were patients in the non-use group.Factors associated with the utilization of each evidence-
based treatment
Factors associated with the utilization of evidence-based
treatment were dependent on admission to a tertiary
hospital, having a more specialized healthcare provider,
prescribed from outpatient clinic, atrial fibrillation,
valvular heart disease and the administration of moresymptom-relieving treatments, such as diuretics
and digoxin.
For the A + B group as shown in Table 2, associated
factors for utilizing evidence-based treatment included
admission to a tertiary hospital, healthcare provider spe-
cialty, prescription from outpatient clinic, the diagnosis
of angina, myocardial infarction, atrial fibrillation or
valvular heart disease, and the administration of inotro-
pics, antithrombotic agents, nitrate, or lipid-lowering
agents. Chronic lung disease was negative associated
factor in utilization of A + B group and B group, while
it was positive associated factor in A group and
Aldo group.
For group A, associated factors for utilization were
similar to those of the A + B group and included admis-
sion to a tertiary hospital, healthcare provider specialty
and prescription from outpatient clinic, but patients with
end-stage renal disease were less likely to receive ACEi
or ARB treatment.
For group B, relatively young patients and those admit-
ted to a secondary hospital were more likely to receive
beta-blockers, and patients with diabetes or chronic lung
disease were less likely to receive treatment. Digoxin,
diuretics, or inotropic agent use were negative associated
factors in group B.
In the Aldo group, patients who were admitted to
primary or secondary hospital, those with dementia or
transient ischemic attack, and those living in rural areas
were more likely to be treated with only aldosterone
antagonists.
Data from the subgroup of our study population that
was given digoxin and diuretics as compared to those
data from the evidence-based treatment group and the
non-use group are shown in Table 3. Results from the
subgroup analysis were similar as in total study popula-
tion. For A + B subgroup, admission to tertiary hospital,
prescription from outpatient clinic, having myocardial
infarction, atrial fibrillation or valvular heart disease and
prescribed with inotropics, antidiabetic medication or
Table 1 Clinical characteristics related to the utilization of disease-modifying treatments in the study population
Total study population ACEI or ARB and Beta-blockers ACEI or ARB Beta-blockers Aldosterone antagonist None
(N= 28922) (N = 6261) (N = 9540) (N= 2837) (N = 2007) (N =8277)
N (%) 21.7% total 33.0% total 9.8% total 6.9% total 28.6% total
Mean age (SD) 77.5 (7.0) 76.7 (6.8)* 77.7 (7.0) 76.8 (6.7)* 78.4 (6.9) 77.9 (7.2)
Age group, y
65-74 10296 (35.6) 2477 (39.6)* 3299 (34.6) 1117 (39.4)** 604 (30.1)* 2799 (33.8)
75-84 13776 (47.6) 2929 (46.8) 4563 (47.8) 1341 (47.3) 1024 (51.0) 3919 (47.4)
85- 4850 (16.8) 855 (13.7) 1678 (17.6) 379 (13.4) 379 (18.9) 1559 (18.8)
Sex
Women 20927 (72.4) 4420 (70.6)* 6885 (72.2) 2123 (74.8)* 1489 (74.2) 6010 (72.6)
Healthcare provider specialty
Internal medicine 27035 (93.5) 6028 (96.3)** 9108 (95.5)** 2651 (93.4)** 1853 (92.3)** 7395 (89.3)
Others 1887 (6.5) 233 (3.7) 432 (4.5) 186 (6.6) 154 (7.7) 882 (10.7)
Type of hospital
Primary hospital 372 (3.0) 55 (0.9)** 188 (2.0)** 102 (3.6)** 86 (4.3)** 441 (5.3)
Secondary hospital 9801 (33.9) 1035 (16.5) 2800 (29.6) 1035 (36.5) 1018 (50.7) 3913 (47.3)
Tertiary hospital 18249 (63.1) 5171 (82.6) 6552 (68.7) 1700 (59.9) 903 (45.0) 3923 (47.4)
Residence area
Urban 15441 (53.4) 3994 (63.8)** 5384 (56.4)** 1435 (50.6)* 778 (38.8)** 3850 (46.5)
Rural 13481 (46.6) 2267 (36.2) 4156 (43.6) 1402 (49.4) 1229 (61.2) 4427 (53.5)
Source of prescription
Outpatient 22046 (76.2) 5165 (82.5) 8295 (86.9) 2385 (84.1) 1731 (86.2) 4470 (54 )
Cardiovascular disease
Angina 4413 (15.3) 1378 (22.0)** 1485 (15.6)** 509 (17.9)** 193 (17.9) 848 (10.3)
Myocardial infarction 3078 (10.6) 981 (15.7)** 1049 (11.0)** 289 (10.2)** 141 (7.0) 618 (7.5)
Transient ischemic stroke 4609 (15.9) 1027 (16.4) 1364 (14.3)** 515 (18.2) 325 (16.2) 1378 (16.7)
Peripheral artery disease 1255 (4.3) 329 (5.3)* 379 (4.0) 141 (5.0)* 70 (3.5) 336 (4.1)
Arterial fibrillation or flutter 5720 (19.8) 1780 (28.4)** 2089 (21.9)** 567 (20.0)** 362 (18.0)** 922 (11.1)
Valvular heart disease 2548 (8.8) 846 (13.5)** 981 (10.3)** 197 (6.9)** 137 (6.8)** 387 (4.7)
Medical history
Hypertension 11394 (39.4) 2149 (34.3)** 3756 (39.4)* 1364 (48.1)** 670 (33.4)** 3455 (41.7)
Diabetes mellitus 9882 (34.2) 2607 (41.6)** 3454 (36.2)** 892 (31.4)* 591 (29.5) 2338 (28.3)
Hyperlipidemia or dyslipidemia 6624 (22.9) 2041 (32.6)** 2279 (23.9)** 637 (22.5)** 349 (17.4) 1318 (15.9)



















Table 1 Clinical characteristics related to the utilization of disease-modifying treatments in the study population (Cont ued)
Chronic lung disease 9829 (34.0) 2041 (32.6) 3516 (36.9)** 850 (30.0) 832 (41.5)** 2610 (31.5)
Chronic liver disease 4474 (15.5) 983 (15.7) 1521 (15.9) 423 (14.9) 325 (16.2) 1222 (14.8)
Systemic cancer 1389 (4.8) 329 (5.3)* 493 (5.2) 120 (4.2) 84 (4.2) 363 (4.4)
Dementia 2000 (6.9) 320 (5.1)** 548 (5.7)** 210 (7.4)* 161 (8.0) 761 (9.2)
Depression 1517 (5.3) 334 (5.3) 477 (5.0) 153 (5.4) 108 (5.4) 445 (5.4)
Concomitant medication
Diuretics 20810 (76.7) 5484 (88.2)** 7886 (84.1)** 1958 (71.0)** 1702 (86.8)** 3780 (55.6)
Calciumchannel blockers 9944 (36.7) 2408 (38.7) 3139 (33.5)* 1224 (44.4)** 542 (27.7)** 2631 (38.7)
Nitrates 7282 (26.9) 2546 (41.0)** 2514 (26.8)** 795 (28.8)** 352 (18.0)* 1075 (15.8)
Digoxin 11913 (43.9) 2918 (46.9)** 4569 (48.7)** 1072 (38.9)** 1036 (52.9)** 2318 (34.1)
Inotropics 5286 (19.5) 1660 (26.7)** 1813 (19.3)* 358 (13.0)** 282 (14.4)* 1173 (17.2)
Amiodarone 986 (3.6) 359 (5.8)** 353 (3.8)** 94 (3.4)* 37 (1.9) 143 (2.1)
Hydralazine 427 (1.6) 141 (2.3)** 116 (1.2) 55 (2.0)* 22 (1.1) 93 (1.4)
Lipid lowering agents 4465 (16.5) 1667 (26.8)** 1509 (16.1)** 459 (16.6)** 175 (8.9) 655 (9.6)
Anti-diabetic medication 6453 (23.8) 1851 (29.8)** 2302 (24.5)** 600 (21.8)* 374 (19.1) 1326 (19.5)
Anti-thrombotics 17473 (64.4) 5024 (80.8)** 6299 (67.2)** 1860 (67.4)** 1050 (53.6)** 3240 (47.6)
Data for categorical variables are expressed as n (%) and quantitative variables as means (standard deviation). SD: standard deviation.
Variables in each group of evidence based treatments were compared with non user group as control group using chi-square methods or Student’s t test method .




















Table 2 Multivariable logistic regression for factors associated with the utilization of disease-modifying treatments in e entire study population of 28, 922
patients with chronic heart failure
Predictors of utilization Disease-modifying treatment group ACEI or ARB and Beta-blockers ACEI or ARB Beta-blockers Aldosterone antagonist
(71.4% total) (21.7% total) (33.0% total) (9.8% total) (6.9% total)
aPR (95% CI) aPR (95% CI) aPR (95% CI) aPR (95% CI) aPR (95% CI)
Older Age group 0.92 (0.89-0.97) 1.09 (1.05-1.14) 0.86 (0.81-0.91) 1.08 (1.01-1.16)
Women 1.13 (1.03-.1.25)
Specialty of healthcare providers being
internal medicine
1.26 (1.12–1.54) 1.20 (1.13-1.39) 1.28 (1.08-1.42) 0.82 (0.68-0.98)
Tertiary hospital 2.07 (1.85-2.31) 1.95 (1.81-2.11) 1.15 (1.09-1.22) 0.86 (0.79-0.93) 0.56 (0.52-0.62)
Urban residence 1.37 (1.23-1.52) 1.08 (1.00-1.15) 1.19 (1.12-1.26) 0.67 (0.61-0.75)
Outpatient prescription 4.02 (3.31-4.72) 2.76 (2.56-2.97) 5.02 (4.64-5.47) 3.08 (2.65-3.56) 3.39 (2.83-4.03)
Cardiovascular disease
Angina 1.40 (1.38-1.47) 1.12 (1.02-1.20) 0.90 (0.83-0.97) 1.21 (1.08-1.35) 0.78 (0.67-0.92)
Myocardial infarction 1.37 (1.28-1.45) 1.11 (1.04-1.23) 0.81 (0.67-0.97)
Transient ischemic stroke 0.82 (0.71-0.94) 0.85 (0.78-0.91) 1.24 (1.09-1.41)
Peripheral artery disease 0.86 (0.75-0.98)
Arterial fibrillation or flutter 1.36 (1.20-1.56) 1.26 (1.17-1.36) 0.87 (0.81-0.98) 1.17 (1.05-1.31)
Valvular heart disease 1.28 (1.10-1.53) 1.26 (1.14-1.39) 0.76 (0.65-0.89) 0.78 (0.65-0.95)
Medical history
Hypertension 1.09 (1.03-1.15) 1.20 (1.11-1.31) 0.63 (0.57-0.70)
Diabetes mellitus 1.26 (1.14-1.40) 1.08 (1.02-1.16) 1.10 (1.04-1.16) 0.80 (0.74-0.88)
Hyperlipidemia or dyslipidemia 0.85 (0.77-0.94)
End-stage renal disease 1.30 (1.16-1.45) 0.78 (0.70-0.88)
Chronic lung disease 0.67 (0.54-0.87) 0.83 (0.77-0.89) 1.13 (1.07-1.19) 1.31 (1.19-1.45)
Dementia 0.83 (0.75-0.92) 0.81 (0.74-0.88)
Concomitant medication
Diuretics 3.41 (3.21-3.65) 1.87 (1.71-2.05) 1.29 (1.13-1.31) 0.82 (0.77 -0.92) 2.24 (1.94-2.58)
CCB 1.18 (1.11-1.26) 0.87 (0.82-0.93) 0.70 (0.63-0.78)
Nitrates 1.79 (1.61-2.01) 1.51 (1.41-1.62) 0.85 (0.79-0.91) 1.30 (1.19-1.42) 0.75 (0.66-0.86)
Digoxin 1.32 (1.24-1.53) 1.23 (1.17-1.30) 1.28 (1.19-1.37)
Hydralazine 1.60 (1.09-2.38) 1.61 (1.28-2.02) 0.73 (0.58-0.92) 1.12 (1.02-1.28)
Inotropics 1.59 (1.41-1.79) 1.43 (1.33-1.54) 0.92 (0.86-0.98)



















Table 2 Multivariable logistic regression for factors assoc ted with the utilization of disease-modifying treatments in the entire study population of 28, 922
patients with chronic heart failure (Continued)
Anti-diabetic medication 1.92 (1.80-2.05) 1.12 (1.04-1.20) 0.65 (0.58-0.72)
Anti-thrombotics 1.88 (1.69-2.09) 1.78 (1.65-1.92) 0.70(0.62-0.79)
Adjusted for demographic factors (age, gender, residence area, utilization of h spital type, specialty of health care providers and type of prescription resources), previous cardiovascular diseases (angina, myocardial
infarction, valvular heart disease, atrial fibrillation or flutter, transient ischemic ttack), systemic medical diseases (, hypertension, hyperlipidemia, chronic lung disease, end stage renal disease) and concomitant
medications (heart failure medication, antidiabetic drugs).






















Table 3 Multivariable logistic regression for factors associated with the utilization of disease-modifying treatment in 10,091 individuals administered digoxin
and diuretics for chronic heart failure
Predictors of utilization Disease-modifying treatments group ACEI or ARB and Beta-blockers ACEI or ARB Beta-blockers Aldosterone antagonist
(84.8% total) (26.9% total) (40.4% total) (8.5% total) (9.0% total)
aPR (95% CI) aPR (95% CI) aPR (95% CI) aPR (95% CI) aPR (95% CI)
Older Age group 0.91 (0.84-0.97) 1.07 (1.01-1.14) 0.87 (0.78-0.96)
Women 1.16 (1.05-1.29) 0.83 (0.71-0.97)
Specialty of healthcare providers being
internal medicine
1.37 (1.09-1.71) 1.23 (1.01-1.49)
Tertiary hospital 1.78 (1.49-2.12) 1.94 (1.73-2.16) 1.12 (1.03-1.22) 0.78 (0.68-0.88) 0.55 (0.48-0.64)
Urban residence 1.46 (1.23-1.74) 1.19 (1.09-1.29) 0.72 (0.62-0.84)
Outpatient prescription 3.87(2.95-4.57) 2.19 (1.95-2.46) 3.17 (2.75-3.64) 2.18 (1.80-2.64) 2.30 (1.69-3.05)
Cardiovascular disease
Myocardial infarction 1.19 (1.03-1.36)
Transient ischemic stroke 0.78 (0.68-0.86) 1.51 (1.25-1.83)
Arterial fibrillation or flutter 1.54 (1.28-1.84) 1.37 (1.24-1.51) 0.90 (0.83-0.99)
Valvular heart disease 1.23 (1.08-1.41) 0.71 (0.54-0.93)
Medical history
Hypertension 1.10(1.02-1.22) 0.62 (0.53-0.73)
Diabetes mellitus 1.32 (1.10-1.56) 1.09 (1.01-1.20) 0.84 (0.71-0.98)
Hyperlipidemia or dyslipidemia 0.78 (0.65-0.93)
End-stage renal disease 0.78 (0.68-0.86)
Chronic lung disease 0.84 (0.76-0.93) 1.13 (1.03-1.23) 0.86 (0.74-0.93) 1.15 (1.00-1.34)
Dementia 0.61 (0.42-0.90) 0.84 (0.70-0.99) 1.41 (1.09-1.82)
Depression
Concomitant medication
CCB* 1.28 (1.15-1.42) 0.82 (0.75-0.90) 1.31 (1.13-1.53) 0.76 (0.64-0.90)
Nitrates 1.39 (1.21-1.60) 1.33 (1.20-1.47) 0.73 (0.61-0.87)
Inotropics 1.78 (1.48-2.16) 1.53 (1.37-1.69) 0.72 (0.60-0.86) 0.68 (0.56-0.83)
Hydralazine 1.64 (1.14-2.37)
Lipid-lowering agents 1.93 (1.52-2.48) 1.61 (1.43-1.83) 0.46 (0.34-0.62)
Anti-diabetic medication 1.14 (1.01-1.25)
Anti-thrombotics 1.63 (1.35-1.96) 1.55 (1.37-1.75) 0.59 (0.49-0.67)
Adjusted for demographic factors (age, gender, residence area, utilization of hospital type, specialty of health care providers and type of prescription resources), previous cardiovascular diseases (angina, myocardial
infarction, valvular heart disease, atrial fibrillation or flutter, transient ischemic attack), systemic medical diseases (hypertension, hyperlipidemia, chronic lung disease, end stage renal disease) and concomitant
medications (heart failure medication, antidiabetic drugs).
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tors. Chronic lung disease was negative associated factor
for utilization of beta blocker treatment in our subgroup
analysis. End stage renal disease was negative associated
factor in A subgroup. Beta blocker treatment subgroup
were relatively young and admission to tertiary hospital
was negative associated factor.
Discussion
This nationwide study revealed the utilization patterns of
evidence-based pharmacologic treatment among elderly
heart failure patients. Our study indicated that evidence-
based treatment is underutilized in elderly heart failure
patients, which is similar to the findings of many other
studies.
The evidence-based treatment group was more likely
to be admitted to tertiary hospitals, and their healthcare
providers were more specialized than those of patients in
the non-use group. Although we did not find the subspe-
cialty of internal medicine in our data set, we hypothe-
sized that most internal medicine care providers would
be cardiologists. The evidence-based treatment group
was more likely to have coexisting cardiovascular dis-
eases, such as angina, myocardial infarction, atrial fibril-
lation, and valvular heart disease, and comorbidities,
such as diabetes and hyperlipidemia.
The non-use group was more likely to have been ad-
mitted to a primary or secondary hospital and treated by
less specialized healthcare providers and was also more
likely to have dementia and living in rural area. And rate
of prescriptions from outpatient setting in non use groupFigure 2 Rates of evidence-based treatment in elderly heart failure pawas 54%, which was lower than that of evidence based
treatment group, where rate was 76%. Therefore, it could
be inferred that the non-use group was more likely to be
institutionalized. Shibata et al [10]., studied the
utilization pattern of evidence-based treatment for heart
failure in institutionalized elderly patients and found pre-
scription rates to be low; the frequency of ACEi and
ARB treatment was 51%, and the frequency of beta-
blocker treatment was 16%.
When considering the associated factors for evidence-
based treatment in elderly heart failure patients, the spe-
cialty of the treating healthcare providers and the type of
hospital were important factors. This may be related to
medication costs and reimbursements. If a patient is
institutionalized due to dementia, the percentage of the
fee that the national healthcare insurance system covers
is limited, and the hospital should thus attempt to reduce
medication and examination costs. Another factor
related to the utilization of evidence-based treatment
may be the healthcare providers. Beta-blockers have been
traditionally misunderstood as aggravating chronic ob-
structive pulmonary disease or poor glycemic control in
diabetes. However, several studies [26,27] have suggested
that patients with chronic obstructive pulmonary disease
tolerate selective beta-blockers well, although these med-
ications should be administered at the lowest possible
dose and require close monitoring. Carvedilol, the most
frequently used beta-blocker for patients with heart fail-
ure, can also be safely prescribed to diabetic patients [28]
because it has neutral effects on blood glucose levels.
Many studies have shown that evidence-based beta-tients.
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prescribed for diabetic heart failure patients because
these treatments have significant health benefits for all
causes of mortality. Our data suggest that many physi-
cians appear reluctant to prescribe beta-blockers for
patients with chronic lung disease or diabetes.
Many researchers from other countries have studied
the utilization patterns of evidence-based treatment in
heart failure. Research using the Medicare database [12]
for elderly populations with heart failure found that the
prescription rate of those prescribed only ACEi or ARB
treatment was 27.9%. The rate of beta-blocker prescrip-
tion was 15.7%, and patients were prescribed both treat-
ments at a rate of 28.4%. Data from the Registry to
Improve the Use of Evidence-Based Heart Failure Ther-
apies in the Outpatient Setting (IMPROVE HF) [30]
indicated that the prescription rate for ACEi or ARBs
was 79.3%, and that for beta-blockers was 85.8%. This
suggested that the utilization patterns of evidence-based
treatment are dependent on the database that is used for
the analysis. For comparability with our data, we
searched articles using claims databases.
Gislason et al [31]., studied the persistent use of
evidence-based pharmacotherapy in heart failure using
the Danish National Patient Registry claims database.
Prescription was defined as treatment initiation after dis-
charge from a hospital admission due to heart failure,
which was similar to our study design. The prescription
rate for ACEi or ARB treatment was 43%. Beta-blockers
were prescribed at a rate of 27%, while spironolactone
was prescribed at a rate of 19%.
Another study was published using a population-based
cohort (1999–2001) of 9,942 patients with heart failure
who had been hospitalized in Ontario, Canada [32].
These researchers investigated the prescription rates of
evidence-based treatment for patients admitted to the
hospital due to heart failure after their discharge. The
prescription rate of ACEi or ARB treatment was approxi-
mately 77%, while that of beta-blockers was 33%; how-
ever, the authors stratified prescription rates with respect
to the validated heart failure risk scores. One study [9]
used the Euro Heart Survey on Heart Failure, which
included 46,788 heart failure patients from 115 hospitals
in 24 ESC member countries. These data showed that
the prescription rate for ACEi or ARB treatment was
62%, and the beta-blocker prescription rate was 37%.
The prescription rate of ACEi or ARB treatment was
54.7% for our total study population and 67.3% when
the population using diuretics and digoxin was ana-
lyzed, as shown in Figure 2. Similarly, the prescription
rate of beta-blockers was 31.5% for the total study
population and 35.4% in the population using diuretics
and digoxin. Some of the underutilization in beta-
blockers could be due to recent hospitalization of heartfailure patients, because stabilization of patient’s status
should be prior to initiating beta blockers.
Our data suggested that the non-use group may con-
sist of institutionalized patients with dementia and that
healthcare system factors, such as medication cost and
reimbursement, healthcare provider factors, such as
specialty or knowledge, and patient factors, such as
comorbidities, could contribute to the underutilization
of evidence-based pharmacologic treatment in heart
failure.
We used the KHIRA claims database to ensure high
generalizability and eliminate recall and selection bias.
Our study results reflected the actual heart failure popu-
lation, and because we used the National Health Insur-
ance System, we were able to obtain detailed
information concerning the medications that were used
to treat diseases coded by the International Classifica-
tion Codes. Thus, we were able to estimate the non-
use group.
However, our study had several limitations. First, the
diagnosis of heart failure in the KHIRA database was not
validated, although a validity study that compared diag-
noses by ICD-10 codes to clinical information obtained
using the medical records showed a positive predictive
value of approximately 70% [33].
Second, our study was limited because data concerning
the left ventricular ejection fraction were not available.
Therefore, our population had potentially considerably
more diverse clinical characteristics, although we
attempted to adjust for this limitation by including many
comorbidities and medications. We also analyzed sub-
groups according to digoxin and diuretic use, which
represented symptom-relieving heart failure treatment,
and the results did not differ.
Third, the contraindication of evidence-based treat-
ment could not be clearly defined. In the non-use group,
long-term bedridden status may contraindicate beta-
blocker utilization or cause patients to be intolerable
state in lowering their blood pressure.Conclusions
In conclusion, an underutilization of evidence-based
treatments was observed in elderly Korean heart failure
patients. Coexisting cardiovascular disease severity and
concurrent medications were associated with a greater
use of evidence-based treatment. The specialty of the
healthcare providers, prescription from outpatient clinic
and the hospital type were important factors for utilizing
evidence-based treatment. Our results could be related
to the healthcare system, various healthcare provider fac-
tors and patient factors.
Further research should focus on improving the quality
of treatment programs for elderly heart failure patients.
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